Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through three segments: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. The Retail Pharmacy USA segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides specialty pharmacy services and mail services. As of August 31, 2020, this segment operated 9,021 retail stores under the Walgreens and Duane Reade brands in the United States; and six specialty pharmacies. The Retail Pharmacy International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty stores and optical practices, as well as through boots.com and an integrated mobile application. This segment operated 4,428 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 550 optical practices, including 165 on a franchise basis. The Pharmaceutical Wholesale segment engages in the wholesale and distribution of specialty and generic pharmaceuticals, health and beauty products, and home healthcare supplies and equipment, as well as provides related services to pharmacies and other healthcare providers. This segment operates in the United Kingdom, Germany, France, Turkey, Spain, the Netherlands, Egypt, Norway, Romania, the Czech Republic, and Lithuania. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois.
IPO Year:
Exchange: NASDAQ
Website: walgreensbootsalliance.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | $11.00 → $9.00 | Hold → Sell | Deutsche Bank |
| 2/26/2024 | $23.00 | Market Perform | Leerink Partners |
| 2/20/2024 | Hold → Reduce | HSBC Securities | |
| 1/3/2024 | $21.00 | Underweight | Barclays |
| 12/22/2023 | $27.00 | Hold | HSBC Securities |
| 10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
| 7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
| 6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
| 2/23/2023 | $45.00 | Buy | Loop Capital |
| 11/23/2022 | $39.00 | Underweight | Morgan Stanley |
SCHEDULE 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
13F-HR - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
SC 13E3/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
PRER14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
SCHEDULE 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
S-8 - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Reporting)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
The facility will support nearly 200 stores regionally with the dispensing and shipping of prescriptions, allowing pharmacists to spend more time with patients. Walgreens is continuing to invest in innovative pharmacy solutions with the opening of a new micro-fulfillment center (MFC) in Brooklyn Park, Minnesota. This facility will streamline prescription processing and reduce administrative tasks, freeing up pharmacists to focus more on delivering personalized care to their patients. This new facility will support nearly 200 Walgreens stores across the Midwest, including 145 in Minnesota alone, and is expected to process approximately 13 million prescriptions each year. It will also bring
Walgreens is offering recruitment events for employees and no-hassle prescription transfers for customers impacted by Rite Aid transitions In light of Rite Aid's recent bankruptcy filing, Walgreens is committed to assisting Rite Aid customers and employees who are impacted by store closures in their local community. For customers who want to transfer their prescriptions to Walgreens: We recognize the trust patients have placed in their Rite Aid pharmacists, and Walgreens is here to continue that care with compassion and consistency. Walgreens is dedicated to meeting patients' needs for continued access to trusted, high-quality pharmacy and health services in communities across the countr
First-of-its-kind program aims to reduce pre-requisite costs, which remain common barriers for pharmacy technicians looking to pursue a PharmD degree. Walgreens, the nation's largest independent community pharmacy provider, has teamed up with Guild, the leading talent development company, to launch PharmStart, a first-of-its-kind, fully funded online education program designed to help eligible team members meet the prerequisite requirements for pharmacy school. The program aims to eliminate barriers to pursuing a PharmD degree, tapping into a new pool of talent while also addressing critical challenges in the pharmacist talent pipeline. This press release features multimedia. View the full
Walgreens is calling on the public to help in the fight against prescription drug abuse by participating in National Prescription Drug Take Back Day on Saturday, April 26th, 2025. Drug take-back days are reserved annually for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,500 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misused. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421063789/en/Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025 This public
Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior
Total Consideration Consists of $11.45 per Share in Cash and Additional Potential Value of Up To $3.00 in Cash per WBA Share from Future Monetization of VillageMD Businesses Sycamore and WBA Combine Retail and Healthcare Expertise to Better Position WBA to Accelerate Turnaround Plan Walgreens Boots Alliance (NASDAQ:WBA) (the "Company" or "WBA") today announced that it has entered into a definitive agreement to be acquired by an entity affiliated with Sycamore Partners ("Sycamore"), a private equity firm specializing in retail, consumer and distribution-related investments. The total value of the transaction represents up to $23.7 billion1. WBA shareholders will receive total consideratio
The Chicagoland-based companies team up to offer on-demand delivery of thousands of everyday essentials CHICAGO and DEERFIELD, Ill., Feb. 20, 2025 /PRNewswire/ -- Grubhub announced today that it has teamed up with Walgreens to bring Walgreens and Duane Reade locations nationwide to its marketplace. Through this collaboration, customers have access to 15,000 items for on-demand delivery — including beauty, health and wellness, snacks, personal care, household items, toys, and more. Grubhub is enhancing the customer experience by expanding its marketplace offerings to include Walgreens and Duane Reade, broadening access to everyday essentials. Grubhub's data shows that customers who shop from
NationsBenefits®, the leading healthcare fintech, supplemental benefits, and outcomes platform, today announced their latest retail integration with Walgreens, one of the nation's leading integrated healthcare and pharmacy companies. This collaboration allows members of NationsBenefits' more than 100 health plan partners to use their Benefits Mastercard® Prepaid Card at Walgreens locations nationwide, gaining seamless access to eligible over-the-counter (OTC) health and wellness products. Powered by NationsBenefits' proprietary Basket Analyzer Service (BAS) and Mastercard's payment network, this integration sets a new standard for point-of-sale innovation in healthcare. "At NationsBenefits
Latest data shows high levels of flu in most states, including significantly higher flu activity across the country when compared to the same time last year The Walgreens Flu Index has tracked its fourth consecutive week of increasing flu activity, with most states across the country experiencing high levels of flu. Overall, U.S. flu activity over the last four weeks is significantly higher when compared to the same time last year – flu activity from the week ending February 8, 2025, was 204% higher compared to the week ending February 10, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214616891/en/For 11 years, the W
Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional
Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior
Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors is suspending the company's cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts. This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, as the company works toward achieving a retail pharmacy-led turnaround underpinned by a sustainable economic model. The company's cash needs over the next several years, including with respect to litigation and debt refinancing,
Company moves earnings date with Securities and Exchange Commission and U.S. stock markets closed on January 9, the previously scheduled date, in honor of late former President Jimmy Carter Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Friday, January 10, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The company today announced it is moving the previously scheduled earnings date of January 9 back one day, as the Securities and Exchange Commission and U.S. stock markets will be closed on the 9th in observance of a national day of mourning for former President Jimmy Carter. The
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fiscal year 2025 first quarter results at 7 a.m. ET on Thursday, January 9, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 175-year heritage of caring for communities. A trusted, global innovator in retail
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on Dec. 12, 2024, to stockholders of record as of Nov. 18, 2024. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 368 straight quarters (92 years). About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail pharmacy with approximately 1
Fourth Quarter In Line with Expectations; Announces Accretive Footprint Optimization Program Fourth quarter financial results Fourth quarter loss per share1 was $3.48 versus loss per share of $0.21 in the year-ago quarter. Loss per share in the current quarter includes a non-cash charge for valuation allowance on deferred tax assets primarily related to opioid liabilities recognized in prior periods, and non-cash impairment charges for CareCentrix goodwill and equity investment in China Adjusted earnings per share (Adjusted EPS2) was $0.39, down 40.8 percent on a constant currency basis driven by net reimbursement pressure, lapping the reversal of incentive accruals, and prior year sa
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) will release its fourth quarter and 2024 fiscal year-end results at 7 a.m. ET on Tuesday, October 15, 2024, followed by a one-hour conference call with WBA management beginning at 8:30 a.m. ET. The conference call will be simulcast through the WBA investor relations website at: http://investor.walgreensbootsalliance.com. A replay will be archived on the website for 12 months after the call. About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovato
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors has declared a quarterly dividend of 25 cents per share, unchanged from the previous quarter. The dividend is payable on Sept. 12, 2024, to stockholders of record as of Aug. 21, 2024. Walgreens Boots Alliance and its predecessor company, Walgreen Co., have paid a dividend in 367 straight quarters (91 years). About Walgreens Boots Alliance Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities. A trusted, global innovator in retail pharmacy with approximatel
Lowering Guidance in Continued Challenging Environment; Provides Strategic Update Third quarter financial highlights Third quarter earnings per share (EPS)* was $0.40 compared to earnings per share of $0.14 in the year-ago quarter which included a non-cash impairment of pharmacy license intangible assets in Boots UK Adjusted EPS** was $0.63, down 36.6 percent on a constant currency basis compared to the year-ago quarter, including a $0.24 impact from lower sale-leaseback gains, a challenging U.S. retail environment, and recent pharmacy industry trends Third quarter sales increased 2.6 percent year-over-year to $36.4 billion, up 2.5 percent on a constant currency basis Fiscal
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
Barclays initiated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $21.00
HSBC Securities initiated coverage of Walgreens Boots Alliance with a rating of Hold and set a new price target of $27.00
JP Morgan upgraded Walgreens Boots Alliance from Neutral to Overweight and set a new price target of $30.00 from $27.00 previously
Morgan Stanley reiterated coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $27.00 from $37.00 previously
Deutsche Bank downgraded Walgreens Boots Alliance from Buy to Hold and set a new price target of $34.00 from $46.00 previously
Loop Capital initiated coverage of Walgreens Boots Alliance with a rating of Buy and set a new price target of $45.00
Morgan Stanley resumed coverage of Walgreens Boots Alliance with a rating of Underweight and set a new price target of $39.00
For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release
Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc
Dr. Shrank brings extensive healthcare experience, business leadership and clinical expertise to WBA board as the company undergoes strategic turnaround Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced the appointment of William H. Shrank, M.D., to the company's board of directors. Dr. Shrank is globally recognized for his leadership and expertise in healthcare strategy, policy and population health. He joins the WBA board at an important time as the company strengthens its business. Currently, Dr. Shrank is a venture partner with the Bio + Health Team of Andreesen Horowitz, a private venture capital firm, a role he has held since January 2023. He previously served in a numbe
CHICAGO, April 15, 2024 (GLOBE NEWSWIRE) -- Beginning April 15th, Walgreens, a pharmacy and retail leader who plays a critical role in the U.S. healthcare system by providing a wide range of pharmacy and healthcare services, including those that drive equitable access to care for the nation's medically underserved populations, and Foundation for Sarcoidosis Research (FSR), the leading international sarcoidosis organization, are proud to announce its renewed partnership to raise education and awareness about sarcoidosis and the importance of spring vaccinations with all Alabama-based Walgreens stores. As part of April's Sarcoidosis Awareness Month from now through April 30th, all Walgree
Eligible Medicare Advantage members can now use their benefits to purchase approximately 1,700 items digitally for shipping, pickup or same-day delivery Today, Walgreens announced it is the first community pharmacy to accept a broad array of Medicare Advantage supplemental benefits online, through Walgreens.com and the Walgreens app. Eligible members can now shop from a catalog of approximately 1,700 Shop Eligible Products on Walgreens digital channels. Consumers have been able to shop using their Medicare Advantage supplemental benefits in stores since 2019 and this brings even greater convenience with new digital shopping solutions regardless of payment method. This press release featu
Appointment completes CEO Tim Wentworth's Executive Committee Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today named Lanesha Minnix the company's executive vice president (EVP) and global chief legal officer. Minnix, most recently EVP, general counsel and corporate secretary for Ecolab, Inc., will assume her new role with WBA on April 15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240226589815/en/Lanesha Minnix named global chief legal officer, Walgreens Boots Alliance (Photo: Business Wire) Minnix, who will report to WBA CEO Tim Wentworth and serve on his Executive Committee, will oversee the company's global legal, comp
NEW YORK, Feb. 20, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the Dow Jones Industrial Average (DJIA) and Dow Jones Transportation Average (DJTA) effective prior to the open of trading on Monday, February 26: Amazon.com Inc. (NASD:AMZN) will replace Walgreens Boots Alliance Inc. (NASD:WBA) in the Dow Jones Industrial Average. Reflecting the evolving nature of the American economy, this change will increase consumer retail exposure as well as other business areas in the DJIA. The index change was prompted by DJIA constituent Walmart Inc.'s (NYSE:WMT) decision to split its stock 3:1, which will reduce Walmart's index weight due to the price weighted construc
Brings deep healthcare and extensive finance experience Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced the election of Robert L. (Robbie) Huffines to the company's board of directors at its 2024 Annual Meeting of Stockholders. He joins the board as an independent director and will serve on the board's Finance and Technology Committee. Huffines currently serves as Global Chairman of Investment Banking at J.P. Morgan Chase & Co., where he has guided healthcare companies for more than 30 years on strategy, mergers and acquisitions, divestitures and financing. He expects to retire from J.P. Morgan Chase early this year. Huffines brings experience across many healthcare vertic
Take five minutes with Walgreens this holiday season to explore trending, budget-friendly gifts and essentials Walgreens has everything you need to keep things merry and bright – with convenient in-person and online shopping options to save the day, especially when you need help last-minute. According to a new Walgreens U.S. gift giving trend survey, 83% of Americans found themselves getting a gift for someone at the very last minute—a trend even more common among Gen Z (90%) and parents (92%). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231213156937/en/Take five minutes with Walgreens this holiday season. (Photo: Business